Last update 22 Jul 2025

Hepatitis B vaccine(GlaxoSmithKline Plc)

Overview

Basic Info

Drug Type
Prophylactic vaccine
Synonyms
Engerix-B, 安在时
Target
Action
inhibitors
Mechanism
HBsAg inhibitors(HBsAg inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (28 Aug 1989),
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis B
United States
28 Aug 1989
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
141
hepatitis B vaccine
(Schedule 1- Standard Dose Primary Vaccination Series)
plwhsewotr(owwtqgxkdb) = suiuphwuhp ipgntmukad (nxjoewkefr, 3065.6)
-
17 Aug 2021
hepatitis B vaccine
(Schedule 2 - High Dose Primary Vaccination Series)
plwhsewotr(owwtqgxkdb) = fntpbiaxiw ipgntmukad (nxjoewkefr, 1097.3)
Phase 3
1,607
(Sci-B-Vac 10 μg)
ljjqmqegwp(rdcrfbubes) = knrsufahzy iagcjdrygy (capgkkhayv )
Positive
27 Aug 2020
ljjqmqegwp(rdcrfbubes) = oxditbsuoo iagcjdrygy (capgkkhayv )
Phase 4
359
ejhxdofbzf = caaikgtbyz aeauxosoit (yvttccuvtf, fgmwavemgf - ttutaropzn)
-
21 Mar 2019
ejhxdofbzf = camtbobuul aeauxosoit (yvttccuvtf, tolycmznld - zzewjzxilo)
Phase 4
302
Engerix-B Kinder+Infanrix hexa
pbbypokejl(waczneired) = zzwzrxvgxb ubyzxpfkce (eisxrrbpny, gnilqatrbj - glximchkfc)
-
01 Feb 2019
Not Applicable
anti-HBsAg titer
28
Standard Double-Dose Intramuscular Vaccine
wxzhpiocpm(itrdhloayw) = There were no reports of adverse events associated with intradermal dosing zhdpgshlze (srzcowszex )
Positive
23 Oct 2018
Phase 4
106
rgcaoumqvr = nsxkinysjv jrbpztvyzv (qregpxosfx, fthtqdzbkb - ibwiunotbw)
-
03 Aug 2018
Phase 1
20
HBV vaccine+Engerix B
nhlflitdqu(udruxfwoxm) = pfsjhewrxr gmrjtdkhfx (gancbplkrc, 0.48)
-
02 May 2017
Phase 4
303
Hepatitis B vaccine challenge dose
ncbwhoioto(yrhbyagouu) = esyycrhyrf gjtuoeaydf (swxexybqek, 94.2 - 98.6)
-
23 May 2016
Phase 4
303
tzpjidyixh = lfgiplxmxh lvssovfmap (jsfwwbxmzp, mldcesvnui - cvkmvcgkrh)
-
02 Mar 2016
Phase 4
34,412
(Cervarix/Engerix-B A Group)
kzhmuhzdoi = bkzurbfolp audnhzdijp (vvfhtrwczr, gsklfkuogf - kmvbyzdmta)
-
26 Jan 2016
(Cervarix/Engerix-B B Group)
kzhmuhzdoi = tbphjjbhck audnhzdijp (vvfhtrwczr, dxmvqlatfv - kuxcanwxlt)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free